Price$4.81-3.91 (-44.84%)
2026-03-062026-06-09
News · 26 weeks36-29%
2025-12-142026-06-07
Mix1890d
- Other10(56%)
- SEC Filings6(33%)
- Insider1(6%)
- Dividends1(6%)
Latest news
25 items- SECQuoin Pharmaceuticals Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation, and Fast Track Designation previously granted by the U.S. FDA, and Orphan Drug Designation previously granted by the European Medicines Agency- -Quoin is working closely with leading Japanese clinicians to refine clinical and regulatory pathway for approval- ASHBURN, Va., June 04, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that Japa
- SECSEC Form SCHEDULE 13G filed by Quoin Pharmaceuticals Ltd.SCHEDULE 13G - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
- PRQuoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from Investigator-led pediatric study- -Second indication for QRX003, in addition to Netherton Syndrome- ASHBURN, Va., June 02, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for QRX003 for the treatment of Peeling Skin Syndrome (PSS). Pending FDA review, Quoin e
- SECSEC Form 424B3 filed by Quoin Pharmaceuticals Ltd.424B3 - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.SCHEDULE 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
- SECQuoin Pharmaceuticals Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- SECSEC Form 10-Q filed by Quoin Pharmaceuticals Ltd.10-Q - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirmed QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Review – U.S. FDA Granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, Complementing Previously Granted Orphan Drug and Rare Pediatric Disease Designations – Constructive Type C Meeting with FDA: Single Phase 3 Study May Be Sufficient to Support U.S. Marketing Approval; FDA Open to Trial Design Without Traditional Vehicle or Placebo Control – Rare Pediatric Disease Prior
- PRQuoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 7, 2026. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from the first quarter of 2026. About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical compan
- PRCORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsCompany Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be Led By Professor Edel O'Toole, Queen Mary University of London, Globally Recognized Leader in Pachyonychia Congenita Quoin Also Planning to Initiate Investigator Led Studies in Gorlin Syndrome and Tuberous Sclerosis Complex In addition to the Investigator Led Studies Company is Targeting to File Investigational New Drug Application to US Food and Drug Administration for QRX009 for an additional indication in Q3 2026 Quoin has Established Relationships With Key Advocacy Foun
- PRQuoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsCompany Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be Led By Professor Edel O'Toole, Queen Mary University of London, Globally Recognized Leader in Pachyonychia Congenita Quoin Also Planning to Initiate Investigator Led Studies in Gorlin Syndrome and Tuberous Sclerosis Complex In addition to the Investigator Led Studies Company is Targeting to File Investigational New Drug Application to US Food and Drug Administration for QRX009 for an additional indication in Q3 2026 Quoin has Established Relationships With Key Advocacy Foun
- INSIDERSEC Form 4 filed by Stonepine Capital Management, Llc4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- SECSEC Form 10-K filed by Quoin Pharmaceuticals Ltd.10-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- SECQuoin Pharmaceuticals Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe – Advances Proposed Expedited Regulatory Approval Pathways in Japan and Saudi Arabia and Secures Fast Track Designation in the U.S. for QRX003 for NS Subsequent to the End of Q4 – Reports Continued Clinical Progress for QRX003 in Netherton Syndrome Clinical Studies including Data Supporting Longer Term Durable Treatment Effect and Safety Profile – Pediatric NS Study Expanded to 7 Children Now Actively Treated with QRX003, Largest Cohort of This Age Group Ever Studied – Ongoing Clinical Data Continues to Support Development of QR
- PRQuoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeFDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront vehicle or placebo control Quoin remains on track to initiate a Phase 3 study and complete Phase 3 patient recruitment in 2026 and potentially file for NDA approval in 2027 ASHBURN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today provided a clinical and regulatory update from its recent constructive Type C meeting
- PRQuoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company
- SECSEC Form 8-K filed by Quoin Pharmaceuticals Ltd.8-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
- PRQuoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for QRX003 in Netherton Syndrome — ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on d
- PRNETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton SyndromeASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) today highlighted the continued growth of its NETHERTON NOW awareness campaign, which seeks to amplify the voices of patients, caregivers and clinicians impacted by Netherton Syndrome, a rare genetic disease with no approved treatment or cure. Rare Disease Day, observed annually on the last day of February during Rare Disease Month, was established in 2008 by EURORDIS to raise awareness of rare conditions and the profound challenges faced by those living with them. While each rare disease affects a relatively small population, collectively rare diseases impact
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quoin Pharmaceuticals Ltd.SCHEDULE 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
- INSIDERSEC Form 4 filed by Chief Financial Officer Lawlor Sally Bridget4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- INSIDERSEC Form 4 filed by Director Cooper Joseph Patrick4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
- INSIDERSEC Form 4 filed by Director Culverwell Anthony James4 - Quoin Pharmaceuticals, Ltd. (0001671502) (Issuer)
QNRX FAQ
6 questionsWhat does Quoin Pharmaceuticals Ltd. do?
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.Where does QNRX stock trade?
Quoin Pharmaceuticals Ltd. (QNRX) is listed on NASDAQ.What sector and industry is QNRX in?
Quoin Pharmaceuticals Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.When did Quoin Pharmaceuticals Ltd. go public?
Quoin Pharmaceuticals Ltd. (QNRX) completed its IPO in 2016.What companies are similar to QNRX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare QNRX side-by-side with any of them on Quantisnow.How can I track QNRX on Quantisnow?
Quantisnow aggregates Quoin Pharmaceuticals Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QNRX to receive live email and push alerts on every new disclosure.